Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health Inc chief accounting officer James M. Meer reported a tax-related share disposition. On the reported date, he transferred 1,389 shares of Common Stock at $24.88 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 66,732 Common Stock shares.
Elanco Animal Health chief accounting officer James M. Meer reported equity compensation and related tax withholding transactions in company common stock. He received grants classified as restricted stock units covering 9,596 shares and 5,209 shares, both at a stated price of $0.00 per share. A separate transaction disposed of 4,787 shares at $26.40 per share to satisfy tax liability by delivering shares. The restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Rajeev A. Modi reported multiple equity awards and related tax withholding transactions. On March 1, 2026, he received 29,025 employee stock options and 2,532 deferred stock units at no cost. He was also granted 41,690 shares of common stock and an additional 14,205 restricted stock units, all as equity awards.
The stock options and restricted stock units each vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle in stock or cash upon termination of employment under the Executive Deferral and Stock Match Plan. To cover tax obligations, 19,375 common shares were disposed of at $26.40 per share through share delivery. Following these transactions, Modi directly owned 160,293 shares of Elanco common stock as of March 1, 2026.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported several equity-award transactions dated March 1, 2026. He acquired an employee stock option covering 243,809 shares and deferred stock units covering 6,593 shares. He also received grants of 397,041 and 119,319 shares of common stock. The restricted stock units and options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle upon termination of employment or under the Executive Deferral and Stock Match Plan. A separate transaction disposed of 229,982 shares of common stock at $26.40 per share for tax-withholding purposes, leaving 1,970,477 shares of common stock held directly, plus 167,000 shares held indirectly by a revocable trust and shares previously acquired under the employee stock purchase plan.
Elanco Animal Health executive Jose Manuel Correia de Simas reported multiple equity compensation movements. He received an employee stock option grant for 23,220 shares at an exercise price of $0.0000 per share and 937 deferred stock units, both recorded as derivative awards.
He also acquired 21,507 and 11,364 shares of common stock as restricted stock unit grants, while 9,883 shares of common stock were disposed of at $26.40 per share to cover taxes, a tax-withholding disposition rather than an open-market sale. Footnotes state the option and stock unit grants vest in thirds on March 1, 2027, March 1, 2028, and March 1, 2029, with certain deferred units vesting on December 31, 2027.
Elanco Animal Health Inc officer Ramiro Martin Cabral reported several equity awards and related share movements. On March 1, 2026, he received an award of 42,570 stock options and separate grants of 60,053 and 20,834 shares of common stock at no cost.
The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, subject to continued service. A separate disposition of 30,150 common shares at $26.40 per share was reported as a tax-withholding transaction, leaving 269,532 common shares held directly afterward.
Elanco Animal Health executive Grace McArdle reported new equity awards and related tax withholding transactions. On March 1, 2026 she received employee stock options for 29,025 shares and grants of 30,110 and 14,205 shares of common stock at no cost. A total of 12,337 shares of common stock at $26.40 per share were disposed of to cover tax liabilities. The options and restricted stock units vest in three equal installments on March 1, 2027, 2028, and 2029.
Elanco Animal Health executive David S. Kinard reported multiple equity awards and related tax withholding transactions. On March 1, 2026 he received 19,350 employee stock options and separate grants of 33,087 and 9,470 shares of common stock at no cost. A total of 15,377 common shares were disposed of at $26.40 per share to cover tax liabilities, leaving him with 217,697 common shares directly owned. The stock options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported equity awards that increase his stake in the company. He received an employee stock option grant for 48,375 shares at a price of $0.0000 per share and a separate grant of 23,675 shares of common stock, both classified as grant or award acquisitions.
According to the disclosure, the stock options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The restricted stock units underlying the common stock grant vest on the same schedule. After the common stock grant, his directly held common stock position is 148,652 shares, which includes 744 shares acquired under the company’s employee stock purchase plan on January 31, 2026.
Elanco Animal Health general counsel and corporate secretary Shiv O'Neill reported equity compensation changes. On March 1, 2026, O'Neill received 29,993 stock options and 33,087 shares of common stock as grant or award acquisitions, all held directly.
The filing also shows a grant of an additional 14,679 common shares and a tax-withholding disposition of 13,111 common shares at $26.40 per share to cover tax obligations. The options and restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.